Moderna, Inc. (MRNA)
NASDAQ: MRNA · Real-Time Price · USD
59.81
+0.64 (1.08%)
At close: Aug 10, 2026, 4:00 PM EDT
60.70
+0.89 (1.49%)
Pre-market: Aug 11, 2026, 9:23 AM EDT
Moderna Revenue
Moderna had revenue of $145.00M in the quarter ending June 30, 2026, with 2.11% growth. This brings the company's revenue in the last twelve months to $2.23B, down -27.62% year-over-year. In the year 2025, Moderna had annual revenue of $1.94B, down -39.93%.
Revenue (ttm)
$2.23B
Revenue Growth
-27.62%
P/S Ratio
10.72
Revenue / Employee
$474,043
Employees
4,700
Market Cap
23.88B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.94B | -1.29B | -39.93% |
| Dec 31, 2024 | 3.24B | -3.61B | -52.75% |
| Dec 31, 2023 | 6.85B | -12.42B | -64.45% |
| Dec 31, 2022 | 19.26B | 792.00M | 4.29% |
| Dec 31, 2021 | 18.47B | 17.67B | 2,200.25% |
| Dec 31, 2020 | 803.00M | 743.00M | 1,238.33% |
| Dec 31, 2019 | 60.00M | -75.07M | -55.58% |
| Dec 31, 2018 | 135.07M | -70.76M | -34.38% |
| Dec 31, 2017 | 205.83M | 97.43M | 89.88% |
| Dec 31, 2016 | 108.40M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 6.13B |
| Incyte | 5.82B |
| Alnylam Pharmaceuticals | 4.80B |
| Jazz Pharmaceuticals | 4.60B |
| Genmab | 4.13B |
| BioNTech SE | 3.03B |
| Royalty Pharma | 2.54B |
| Insmed | 1.14B |
MRNA News
- 4 days ago - These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks - Barrons
- 4 days ago - This new kind of flu shot by Moderna has just been approved by the FDA - Fast Company
- 4 days ago - Moderna Stock Flashing Intriguing ‘Buy The Dip' Signal - Forbes
- 4 days ago - Moderna Stock Slips Despite FDA Approval for New Flu Shot mFlusiva - TipRanks
- 5 days ago - Moderna Stock Rises as Flu Vaccine Approval Offers Spark for a Post-Pandemic Future - Barrons
- 5 days ago - Sandisk, AppLovin, Moderna, and More Stocks That Explain Today's Market - Barrons
- 5 days ago - Moderna receives FDA approval for mFlusiva in adults 50 years, older - TheFly
- 5 days ago - Moderna Stock (MRNA) Jumps on U.S. Approval for New Flu Shot Type — Why This Matters - TipRanks